{
    "cancer_info": {
        "cancer_name": "Pediatric Acute Lymphoblastic Leukemia"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Bone marrow aspirate/biopsy (morphology, flow cytometry)",
            "Cytogenetics/FISH (BCR::ABL1, KMT2A, ETV6::RUNX1, hypodiploidy)",
            "Molecular profiling (CRLF2, JAK2, IKZF1, NOTCH1, FBXW7)",
            "Lumbar puncture with CSF analysis (CNS status classification)",
            "Multiparameter flow cytometry (MRD monitoring)",
            "Next-generation sequencing (NGS) for MRD detection",
            "Karyotyping",
            "RT-PCR for BCR::ABL1",
            "Low-density array for BCR::ABL1-like signatures",
            "CT/MRI head (if neurologic symptoms)",
            "Chest X-ray (mediastinal mass evaluation)",
            "Scrotal ultrasound (testicular involvement)",
            "PET-CT (if lymphoblastic lymphoma suspected)",
            "Echocardiogram (if anthracyclines planned)",
            "Pharmacogenomics testing (TPMT, NUDT15)",
            "CBC with differential",
            "Liver function tests (LFTs)",
            "Tumor lysis panel (LDH, uric acid, electrolytes)",
            "Coagulation studies (PT, PTT, fibrinogen, D-dimer)",
            "Pregnancy testing",
            "Viral serologies (HSV, CMV, EBV)",
            "Immunoglobulins"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Initial risk stratification",
            "risk_group": "Standard Risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "B-ALL, BCR::ABL1-negative",
                    "plan_name": "COG AALL0932",
                    "plan_details": "Dexamethasone, vincristine, pegaspargase, methotrexate",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Initial risk stratification",
            "risk_group": "High Risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "B-ALL, BCR::ABL1-negative",
                    "plan_name": "COG AALL1131",
                    "plan_details": "Cyclophosphamide, cytarabine, daunorubicin added to backbone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "BCR::ABL1-positive",
                    "plan_name": "COG AALL1631",
                    "plan_details": "Chemotherapy + TKI (imatinib/dasatinib)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "T-ALL",
                    "plan_name": "COG AALL0434",
                    "plan_details": "Nelarabine + augmented BFM backbone",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Initial risk stratification",
            "risk_group": "Very High Risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Infant ALL with KMT2A rearrangements",
                    "plan_name": "Interfant Regimen",
                    "plan_details": "Intensive chemotherapy ± blinatumomab",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Post-induction risk stratification",
            "risk_group": "MRD ≥0.01% at Day 29",
            "treatment_plans": [
                {
                    "treatment_line": "Treatment intensification",
                    "patient_subgroup": "B-ALL",
                    "plan_name": "Blinatumomab",
                    "plan_details": "CD19/CD3 bispecific antibody for MRD eradication",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory Disease",
            "risk_group": "First relapse",
            "treatment_plans": [
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "B-ALL",
                    "plan_name": "Blinatumomab or Inotuzumab",
                    "plan_details": "CD19/CD3 bispecific antibody or CD22 antibody-drug conjugate",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "T-ALL",
                    "plan_name": "Nelarabine-based regimens",
                    "plan_details": "Nelarabine ± chemotherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory Disease",
            "risk_group": "Multiple relapse/refractory",
            "treatment_plans": [
                {
                    "treatment_line": "Third-line treatment",
                    "patient_subgroup": "KMT2A-rearranged ALL",
                    "plan_name": "Revumenib",
                    "plan_details": "Menin inhibitor",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Third-line treatment",
                    "patient_subgroup": "B-ALL",
                    "plan_name": "Tisagenlecleucel",
                    "plan_details": "CD19 CAR T-cell therapy",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Other recommended"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "MRD: Most powerful prognostic factor; guides treatment intensification; BCR::ABL1: High-risk marker requiring TKIs; KMT2A rearrangements: Poor prognosis in infants, targetable with menin inhibitors; IKZF1 deletions: Inferior EFS independent of MRD; CRLF2/JAK-STAT: Defines BCR::ABL1-like ALL, targetable with JAK inhibitors; TPMT/NUDT15: Predicts thiopurine toxicity requiring dose reduction; ETV6::RUNX1: Favorable prognosis allowing therapy de-escalation"
    },
    "guideline_id": "（2025.V2）NCCN临床实践指南：儿童急性淋巴细胞白血病.txt"
}